Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Compérat

Showing results (101-110 of 243) with videos related to

Pageof 25
Sort By:
Virchows Archiv : an International Journal of Pathology|October 23, 2013
HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial originJustine Varinot, Olivier Cussenot, Morgan Roupret, et al.
Bulletin Du Cancer|July 5, 2017
[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]Luca Campedel, Myriam Kossaï, Paul Blanc-Durand, et al.
World Journal of Urology|April 21, 2021
Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?Moritz Maas, Johannes Mischinger, Eva Compérat, et al.
International Journal of Molecular Sciences|March 27, 2025
<i>CD44</i> Methylation Levels in Androgen-Deprived Prostate Cancer: A Putative Epigenetic Modulator of Tumor ProgressionVirginia Valentini, Raffaella Santi, Valentina Silvestri, et al.
The American Journal of Pathology|December 18, 2019
Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerRenate Pichler, Andrea K Lindner, Eva Compérat, et al.
The Canadian Journal of Urology|March 12, 2018
Analysis of bladder cancer subtypes in neurogenic bladder tumorsQuentin Manach, Olivier Cussenot, Morgan Rouprêt, et al.
Histopathology|July 22, 2014
Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resectionEnrico Munari, Alcides Chaux, Leonel Maldonado, et al.
Neoplasia (New York, N.Y.)|December 17, 2013
Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencingDorothee Pflueger, Andrea Sboner, Martina Storz, et al.
The Prostate|August 6, 2010
Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomyEva Compérat, Morgan Rouprêt, Sarah J Drouin, et al.
Virchows Archiv : an International Journal of Pathology|January 13, 2018
Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP)Solene-Florence Kammerer-Jacquet, Eva Compérat, Lars Egevad, et al.
Pageof 25

Showing results (101-110 of 243) with videos related to

Sort By:
Pageof 25
Virchows Archiv : an International Journal of Pathology|October 23, 2013
HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial originJustine Varinot, Olivier Cussenot, Morgan Roupret, et al.
Bulletin Du Cancer|July 5, 2017
[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]Luca Campedel, Myriam Kossaï, Paul Blanc-Durand, et al.
World Journal of Urology|April 21, 2021
Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?Moritz Maas, Johannes Mischinger, Eva Compérat, et al.
International Journal of Molecular Sciences|March 27, 2025
<i>CD44</i> Methylation Levels in Androgen-Deprived Prostate Cancer: A Putative Epigenetic Modulator of Tumor ProgressionVirginia Valentini, Raffaella Santi, Valentina Silvestri, et al.
The American Journal of Pathology|December 18, 2019
Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerRenate Pichler, Andrea K Lindner, Eva Compérat, et al.
The Canadian Journal of Urology|March 12, 2018
Analysis of bladder cancer subtypes in neurogenic bladder tumorsQuentin Manach, Olivier Cussenot, Morgan Rouprêt, et al.
Histopathology|July 22, 2014
Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resectionEnrico Munari, Alcides Chaux, Leonel Maldonado, et al.
Neoplasia (New York, N.Y.)|December 17, 2013
Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencingDorothee Pflueger, Andrea Sboner, Martina Storz, et al.
The Prostate|August 6, 2010
Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomyEva Compérat, Morgan Rouprêt, Sarah J Drouin, et al.
Virchows Archiv : an International Journal of Pathology|January 13, 2018
Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP)Solene-Florence Kammerer-Jacquet, Eva Compérat, Lars Egevad, et al.
Pageof 25